Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs in Frailty
NCT04919135Phase 2Completed
- Sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
- Start
- Oct 2021
- Primary completion
- Apr 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of human umbilical cord mesenchymal stem cells in frailty syndrome (2 arms), sponsored by Vinmec Research Institute of Stem Cell and Gene Technology. Primary endpoint: Adverse events and serious adverse events up to 9 months. Started Oct 2021; status: completed.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
frailty syndrome
Beyond the preview
Go deeper on NCT04919135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04919135.